Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) were down 9.4% during mid-day trading on Wednesday . The company traded as low as $1.20 and last traded at $1.45. Approximately 1,101 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 12,160 shares. The stock had previously closed at $1.60.
Silence Therapeutics Stock Down 9.4%
The stock’s 50 day moving average is $1.62 and its 200-day moving average is $1.37.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- What is a penny stock? A comprehensive guide
- Cybersecurity Market Set to Double: This ETF Offers Exposure
- There Are Different Types of Stock To Invest In
- Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
